ReviewTherapeutic advances in medical oncology2018
Turning
Review in Therapeutic advances in medical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.The oncologist · 2020Trial
- Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.Targeted oncology · 2019Trial
- New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.Journal of surgical oncology · 2026Article
- Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms.NPJ systems biology and applications · 2025Article
- Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems.Medical oncology (Northwood, London, England) · 2025Review
- Features of Cancer mHealth Apps and Evidence for Patient Preferences: Scoping Literature Review.JMIR cancer · 2023Article
- Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.Journal of cancer research and clinical oncology · 2022Article
- Integrated Network Pharmacology Analysis andMolecules (Basel, Switzerland) · 2021Article
- Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.Advances in therapy · 2021Review
- Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC.Biomedicines · 2021Article
- Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.Therapeutic advances in medical oncology · 2021Article
- Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study.BMJ open · 2020Article
- New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC.Pharmaceutics · 2020Article
- Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC.Translational oncology · 2019Article
- Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study).Translational lung cancer research · 2019Article
- Signaling pathways involved in colorectal cancer progression.Cell & bioscience · 2019Review
- Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer.OncoTargets and therapy · 2019Review
- First-line afatinib for the treatment ofTherapeutic advances in medical oncology · 2019Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the management of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.